Clinical Trial Update: Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating adding abaloparatide to ongoing denosumab therapy versus continued denosumab alone in postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Abaloparatide (abaloparatide)
• Denosumab (denosumab)

Snippet

Sponsor: Hospital for Special Surgery, New York | Conditions: Osteoporosis, Postmenopausal | Phase 4 | Status: ACTIVE_NOT_RECRUITING